Aurora Cannabis (NASDAQ:ACB) reported fiscal first-quarter 2027 net revenue of C$67.6 million, as growth in international medical cannabis sales was offset by lower Canadian medical revenue following reimbursement changes and the company’s planned exit from lower-margin Canadian consumer cannabis operations. International Expansion Centers on GMP CapacityMartin said Aurora is prioritizing international medical cannabis markets, including Germany, Poland, Australia, New Zealand and the U.K. Aurora is one of three active in-country medical cannabis producers with a production and research-and-development license under German cannabis law, Martin said. For the fiscal second quarter, Aurora expects revenue and adjusted EBITDA to be sequentially higher than in the first quarter. About Aurora Cannabis (NASDAQ:ACB)Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta.